Premium
Etoposide in recurrent childhood Langerhans' cell histiocytosis: An Italian cooperative study
Author(s) -
Ceci Adriana,
de Terlizzi Marino,
Colella Roberto,
Balducci Donato,
Toma Maria Grazia,
Zurlo Maria Grazia,
Macchia Pierantonio,
Mancini Antonia,
Indolfi Paolo,
Locurto Margherita,
Calculli Giovanni,
Cristiani Maria,
Castello Manuel
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19881215)62:12<2528::aid-cncr2820621213>3.0.co;2-#
Subject(s) - medicine , langerhans cell histiocytosis , etoposide , histiocytosis , dermatology , pediatrics , pathology , chemotherapy , disease
Eighteen evaluable children with recurrent Langerhans' cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16–213), 200/mg/m 2 /day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug. Complete and partial responses were demonstrated in 15 patients (83.3%). Only one of the 12 children achieving a complete remission has relapsed. No doselimiting major toxicities were registered. Although etoposide might he an effective treatment in recurrent LCH which needs a chemotherapeutic approach, it is emphasized that this drug must be used carefully.